{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:23:39Z","timestamp":1793917419731,"version":"4.8.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017317","name":"Catholic Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["LRAP23"],"award-info":[{"award-number":["LRAP23"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG077202"],"award-info":[{"award-number":["R01 AG077202"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG057195"],"award-info":[{"award-number":["U01 AG057195"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24 AG082930"],"award-info":[{"award-number":["U24 AG082930"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 AG065181"],"award-info":[{"award-number":["U54 AG065181"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["MJFF-023365"],"award-info":[{"award-number":["MJFF-023365"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG082350"],"award-info":[{"award-number":["U01 AG082350"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 AG054345"],"award-info":[{"award-number":["U54 AG054345"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG074879"],"award-info":[{"award-number":["U19 AG074879"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG068193"],"award-info":[{"award-number":["R01 AG068193"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AG072976"],"award-info":[{"award-number":["P30 AG072976"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG072474"],"award-info":[{"award-number":["R01 AG072474"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RD005665"],"award-info":[{"award-number":["RD005665"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24 AG021886"],"award-info":[{"award-number":["U24 AG021886"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.medj.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T10:54:48Z","timestamp":1725879288000},"page":"1206-1226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Yan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0894-8982","authenticated-orcid":false,"given":"Harald","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.08.004_bib1","series-title":"FDA Grants Accelerated Approval for Alzheimer\u2019s Disease Treatment","year":"2021"},{"key":"10.1016\/j.medj.2024.08.004_bib2","series-title":"FDA Grants Accelerated Approval for Alzheimer\u2019s Drug","year":"2021"},{"key":"10.1016\/j.medj.2024.08.004_bib3","series-title":"Leqembi (Lecanemab) [Prescribing Information]","year":"2023"},{"key":"10.1016\/j.medj.2024.08.004_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.medj.2024.08.004_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease","volume":"378","author":"Honig","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib6","unstructured":"A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3). ClinicalTrials.gov identifier: NCT05026866 Updated August 28, 2024. Accessed August 30, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05026866."},{"key":"10.1016\/j.medj.2024.08.004_bib7","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/alz.13542","article-title":"Plasma Abeta42\/Abeta40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease","volume":"20","author":"Rissman","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.medj.2024.08.004_bib8","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat. Aging"},{"key":"10.1016\/j.medj.2024.08.004_bib9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nrd3842-c1","article-title":"Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease","volume":"12","author":"Aisen","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2024.08.004_bib10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.pneurobio.2010.11.005","article-title":"Biomarkers for Alzheimer's disease therapeutic trials","volume":"95","author":"Hampel","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.medj.2024.08.004_bib12","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib13","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-beta Pathway in Alzheimer's Disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.medj.2024.08.004_bib14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1212\/WNL.0000000000009058","article-title":"Biological subtypes of Alzheimer disease: A systematic review and meta-analysis","volume":"94","author":"Ferreira","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.08.004_bib15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","article-title":"Four distinct trajectories of tau deposition identified in Alzheimer's disease","volume":"27","author":"Vogel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib16","doi-asserted-by":"crossref","first-page":"e2673","DOI":"10.1212\/WNL.0000000000012022","article-title":"Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity","volume":"96","author":"Jutten","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.08.004_bib17","series-title":"S1. JPAD: 16th Clinical Trials on Alzheimer's Disease (CTAD) held in Boston, MA","first-page":"S9","article-title":"Lecanemab for early Alzheimer's disease: long term outcomes, predictive biomarkers and novel subcutaneous administration","author":"Van Dyck","year":"2023"},{"key":"10.1016\/j.medj.2024.08.004_bib18","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2024.08.004_bib19","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/alz.13431","article-title":"Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease","volume":"20","author":"Pang","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.medj.2024.08.004_bib20","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","article-title":"Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios","volume":"80","author":"Janelidze","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jamaneurol.2016.4202","article-title":"Associations Between beta-Amyloid Kinetics and the beta-Amyloid Diurnal Pattern in the Central Nervous System","volume":"74","author":"Lucey","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13024-017-0161-4","article-title":"Diurnal oscillation of CSF Abeta and other AD biomarkers","volume":"12","author":"Lucey","year":"2017","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.medj.2024.08.004_bib24","doi-asserted-by":"crossref","first-page":"e89998","DOI":"10.1371\/journal.pone.0089998","article-title":"Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system","volume":"9","author":"Dobrowolska","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2024.08.004_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.wnl.0000256043.50901.e3","article-title":"Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker","volume":"68","author":"Bateman","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.08.004_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ana.25117","article-title":"Effect of sleep on overnight cerebrospinal fluid amyloid beta kinetics","volume":"83","author":"Lucey","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib27","doi-asserted-by":"crossref","first-page":"e1181","DOI":"10.1212\/WNL.0000000000008866","article-title":"Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men","volume":"94","author":"Benedict","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.08.004_bib28","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/alz.13518","article-title":"Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals","volume":"20","author":"Brum","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.medj.2024.08.004_bib29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ana.26891","article-title":"Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset","volume":"95","author":"Li","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib30","doi-asserted-by":"crossref","first-page":"e11170","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib31","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease","volume":"28","author":"Mila-Aloma","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.medj.2024.08.004_bib32","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of Abeta42\/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib33","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease","volume":"29","author":"Horie","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib34","article-title":"Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's disease","author":"Salvado","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.medj.2024.08.004_bib35","doi-asserted-by":"crossref","first-page":"106356","DOI":"10.1016\/j.nbd.2023.106356","article-title":"Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP","volume":"189","author":"Wojdala","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.medj.2024.08.004_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13195-023-01174-0","article-title":"The dynamics of plasma biomarkers across the Alzheimer's continuum","volume":"15","author":"Guo","year":"2023","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.medj.2024.08.004_bib37","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","article-title":"Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease","volume":"69","author":"Blennow","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib38","first-page":"25","article-title":"Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients","volume":"10","author":"Fang","year":"2023","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.medj.2024.08.004_bib39","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","article-title":"The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review","volume":"14","author":"Brand","year":"2022","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.medj.2024.08.004_bib41","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-Head Comparison of 8 Plasma Amyloid-beta 42\/40 Assays in Alzheimer Disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib42","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.medj.2024.08.004_bib63","first-page":"197","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer\u2019s Disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.medj.2024.08.004_bib101","series-title":"Aduhelm (Aducanumab) [Prescribing Information]","year":"2022"},{"key":"10.1016\/j.medj.2024.08.004_bib79","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib102","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.medj.2024.08.004_bib103","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib94","article-title":"Donanemab in Early Symptomatic Alzheimer\u2019s Disease: Biomarker Results from TRAILBLAZER-ALZ 2. Alzheimer\u2019s Association International Conference","author":"Hansson","year":"2023","journal-title":"Amsterdam, Netherlands"},{"key":"10.1016\/j.medj.2024.08.004_bib104","article-title":"Amyloid Reduction: Donanemab Perspective. Alzheimer\u2019s Association International Conference","author":"Sims","year":"2023","journal-title":"Amsterdam, Netherlands"},{"key":"10.1016\/j.medj.2024.08.004_bib105","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1192\/bjo.2023.227","article-title":"TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease","volume":"9","author":"Salloway","year":"2023","journal-title":"BJPsych Open"},{"key":"10.1016\/j.medj.2024.08.004_bib106","article-title":"TRAILBLAZER-ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic alzheimer\u2019s disease - results from 18-months","author":"Salloway","year":"2024","journal-title":"Alzheimer's & Parkinson's Diseases Conference. Lisbon, Portugal"},{"key":"10.1016\/j.medj.2024.08.004_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/alz.065684","article-title":"Gantenerumab treatment increases plasma beta-amyloid(1\u201342) and decreases plasma pTau","volume":"18","author":"Bittner","year":"2022","journal-title":"Alzheimer's & Dementia"},{"key":"10.1016\/j.medj.2024.08.004_bib107","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.medj.2024.08.004_bib81","first-page":"3","article-title":"Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab","volume":"8","author":"Klein","year":"2021","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.medj.2024.08.004_bib108","doi-asserted-by":"crossref","first-page":"P240","DOI":"10.1016\/j.jalz.2018.06.2379","article-title":"O1-09-02: The effect of low doses of gantenerumab on amyloid and tau biomarkers in cerebrospinal fluid (csf) in the marguerite road study.","volume":"14","author":"Voyle","year":"2018","journal-title":"Alzheimer\u2019s Dementia"},{"key":"10.1016\/j.medj.2024.08.004_bib70","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib69","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib80","article-title":"GRADUATE I and II Results: Effect of Subcutaneous Gantenerumab on Fluid Biomarkers of AD Pathology and Neurodegeneration. Alzheimer's & Parkinson's Diseases Conference","author":"Bittner","year":"2023","journal-title":"Gothenburg, Sweden"},{"key":"10.1016\/j.medj.2024.08.004_bib52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.medj.2024.08.004_bib109","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A beta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.medj.2024.08.004_bib110","article-title":"Clinical and biomarker updates from BAN2401 study 201 in early AD. Clinical Trials on Alzheimer\u2019s Disease Congress","author":"Swanson","year":"2018","journal-title":"Barcelona, Spain"},{"key":"10.1016\/j.medj.2024.08.004_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib68","article-title":"Lecanemab: Amyloid Reduction and Evidence of Downstream Biomarker Modification. Alzheimer\u2019s Association International Conference","author":"Irizarry","year":"2023","journal-title":"Amsterdam, Netherlands"},{"key":"10.1016\/j.medj.2024.08.004_bib62","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40265-024-02067-8","article-title":"Effects of Oral ALZ-801\/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer\u2019s Disease","volume":"84","author":"Hey","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.medj.2024.08.004_bib49","first-page":"414","article-title":"Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"JPAD-J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.medj.2024.08.004_bib83","article-title":"Advances in our understanding of amyloid plaque clearing therapies. Alzheimer\u2019s & Parkinson\u2019s Diseases Conference","author":"Mintun","year":"2024","journal-title":"Lisbon, Portugal"},{"key":"10.1016\/j.medj.2024.08.004_bib54","doi-asserted-by":"crossref","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","article-title":"Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease","volume":"76","author":"Ashton","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.medj.2024.08.004_bib65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1083\/jcb.201407065","article-title":"Tau reduction prevents A\u03b2-induced axonal transport deficits by blocking activation of GSK3\u03b2","volume":"209","author":"Vossel","year":"2015","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.medj.2024.08.004_bib46","first-page":"2024","article-title":"Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease","volume":"17","author":"Spies","year":"2012","journal-title":"FBL"},{"key":"10.1016\/j.medj.2024.08.004_bib47","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer's disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.medj.2024.08.004_bib48","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.medj.2024.08.004_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.medj.2024.08.004_bib51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease","volume":"20","author":"Soderberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.medj.2024.08.004_bib55","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barthelemy","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.medj.2024.08.004_bib56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00401-021-02400-5","article-title":"CSF p-tau increase in response to Abeta-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles","volume":"143","author":"Kaeser","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.medj.2024.08.004_bib57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13024-022-00578-0","article-title":"Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels","volume":"17","author":"Murray","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.medj.2024.08.004_bib58","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau Kinetics in Neurons and the Human Central Nervous System","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.medj.2024.08.004_bib59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study","volume":"61","author":"Hampel","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.medj.2024.08.004_bib60","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2024.08.004_bib61","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib64","article-title":"Phase 2 lecanemab early Alzheimer's Disease study biomarker results and correlations with clinical outcomes","author":"Bateman","year":"2022","journal-title":"Alzheimer's & Parkinson's Diseases Conference. Barcelona, Spain"},{"key":"10.1016\/j.medj.2024.08.004_bib66","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JAD-2011-110320","article-title":"JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models","volume":"26","author":"Ploia","year":"2011","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.medj.2024.08.004_bib67","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2024.08.004_bib71","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.medj.2024.08.004_bib72","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","article-title":"Serum neurofilament light levels in normal aging and their association with morphologic brain changes","volume":"11","author":"Khalil","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.medj.2024.08.004_bib73","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib74","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/psp4.12728","article-title":"Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease","volume":"11","author":"Kandadi Muralidharan","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.medj.2024.08.004_bib76","doi-asserted-by":"crossref","first-page":"P1582","DOI":"10.1016\/j.jalz.2019.09.023","article-title":"Population pharmacokinetic\/pharmacodynamic analyses of BAN2401 in patients with early Alzheimer\u2019s disease: correlation of BAN2401 exposure, PET standard uptake value ratio, and cognitive outcomes","volume":"15","author":"Schuck","year":"2019","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.medj.2024.08.004_bib77","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/psp4.12862","article-title":"Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease","volume":"11","author":"Hayato","year":"2022","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.medj.2024.08.004_bib78","series-title":"S1. JPAD: 16th Clinical Trials on Alzheimer's Disease (CTAD) held in Boston, MA","first-page":"S10","article-title":"Preliminary Update on Lecanemab Safety in Clarity AD Open-Label Extension, Including Subcutaneous Formulation","author":"Irizarry","year":"2023"},{"key":"10.1016\/j.medj.2024.08.004_bib84","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/cpt.2536","article-title":"Toward Bridging Unmet Medical Need in Early Alzheimer's Disease: An Evaluation of Beta-Amyloid (Abeta) Plaque Burden as a Potential Drug Development Tool","volume":"111","author":"Zhu","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.medj.2024.08.004_bib85","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2024.08.004_bib86","first-page":"e12404","article-title":"Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease","volume":"9","author":"Gueorguieva","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.medj.2024.08.004_bib87","author":"United Healthcare Services"},{"key":"10.1016\/j.medj.2024.08.004_bib88","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barthelemy","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2024.08.004_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","author":"Jack","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.medj.2024.08.004_bib90","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","article-title":"Alzheimer disease blood biomarkers: considerations for population-level use","volume":"20","author":"Mielke","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.medj.2024.08.004_bib91","first-page":"e12385","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.medj.2024.08.004_bib92","series-title":"Individuals With Early Alzheimer\u2019s Disease","article-title":"Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody","year":"2023"},{"key":"10.1016\/j.medj.2024.08.004_bib93","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","article-title":"Disease staging of Alzheimer's disease using a CSF-based biomarker model","volume":"4","author":"Salvado","year":"2024","journal-title":"Nat. Aging"},{"key":"10.1016\/j.medj.2024.08.004_bib95","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40120-024-00604-x","article-title":"Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial","volume":"13","author":"Sato","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.medj.2024.08.004_bib96","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.3390\/cancers14174131","article-title":"Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.medj.2024.08.004_bib97","series-title":"QALSODY (Tofersen) [Prescribing Information]","year":"2023"},{"key":"10.1016\/j.medj.2024.08.004_bib98","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.tins.2022.12.004","article-title":"The foundation and architecture of precision medicine in neurology and psychiatry","volume":"46","author":"Hampel","year":"2023","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.medj.2024.08.004_bib99","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","article-title":"Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives","volume":"9","author":"Hampel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2024.08.004_bib100","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat. Rev. Neurol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T22:44:46Z","timestamp":1730587486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024003350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":107,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2666634024003350"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.08.004","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}